CoreWeave Q2'25 Earnings Presentation August 12, 2025 1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of applicable securities laws. Such statements are based on our current expectations, forecasts and assumptions and involve risks and uncertainties. These statements include, but are not limited to, statements related to our business; our strategy; our market opportunity and future growth; market trends; impact of investments in sales and marketing; an ...

Q4 FY25 Performance - Revenue reached $480.7 million[9,10,11,13], a 16% increase QoQ[8] and a 67% increase YoY[8] - Non-GAAP gross margin was 37.8%[10], compared to 35.2% in Q3 FY25[10] and 27.8% in Q4 FY24[10] - Non-GAAP operating income was $72.3 million[10], resulting in a 15.0% operating margin[10] - Non-GAAP diluted EPS was $0.88[10], compared to $0.57 in Q3 FY25[10] and $(0.13) in Q4 FY24[10] Segment Performance - Cloud & Networking revenue was $424.1 million[11] - Industrial Tech revenue was $56.6 million[11] Key Growth Drivers - Strong cloud demand, particularly from hyperscale customers, drove revenue growth[8] - Cloud module shipments exceeded the 50% QoQ growth target[8] - EML business approximately doubled compared to Q4 FY24[8] Q1 FY26 Guidance (Non-GAAP) - Revenue is projected to be between $510 million and $540 million[13] - Operating margin is expected to be between 16.0% and 17.5%[13] - Diluted EPS is projected to be between $0.95 and $1.10[13]

Financial Performance - Total revenue increased by 81% year-over-year, reaching $181.4 million in Q2 2025, compared to $100 million in Q2 2024[11] - Molecular Profiling Services revenue grew by 86% year-over-year, amounting to $162.9 million in Q2 2025, up from $87.7 million in Q2 2024[11] - Pharma R&D Services revenue increased by 49% year-over-year, reaching $18.5 million in Q2 2025, compared to $12.4 million in Q2 2024[11] - Clinical ASP improved by 52%, rising from $2,138 in Q2 2024 to $3,256 in Q2 2025[15] - Gross margin increased by 2,514 basis points year-over-year, reaching 62.7% in Q2 2025[15, 42] - Adjusted EBITDA turned positive, reaching $16.7 million in Q2 2025, compared to a loss of $50.9 million in Q2 2024[15, 34] - Free Cash Flow turned positive, reaching $5.9 million in Q2 2025, compared to a loss of $65.5 million in Q2 2024[15, 34] Operational Highlights - Clinical volume grew by 22%, with 50,032 clinical cases completed in Q2 2025[15] - The company's molecular dataset surpassed 900,000+ comprehensive tumor patient profiles, including over 529,000 Whole Exomes and 580,000 Whole Transcriptomes[15, 21] - Caris Assure ASP increased 58.7% year-over-year to $2,519 in Q2 2025[40] - MI Profile ASP increased 53.1% year-over-year to $3,379 in Q2 2025[40] Strategic Initiatives - The Partner Oncology Alliance (POA) expanded to 97 sites with over 1,100 publications[15, 23] - A landmark Caris Assure study was published, validating the single assay across the cancer care continuum[15, 26]

Clinical Trial Updates - Data from the ASPEN-06 trial highlights CD47 expression as a key predictive biomarker, demonstrating a compelling clinical response of evorpacept activity in HER2+ gastric cancer[12] - The Phase 2 ASPEN-Breast evorpacept trial design was updated to enable a CD47 and HER2 biomarker-driven strategy in a single-arm study[12] - Dose escalation was completed in the Sanofi-sponsored trial of evorpacept with SARCLISA® and dexamethasone in previously treated multiple myeloma, with Sanofi moving into dose optimization[12] - The first patient is anticipated to be enrolled in August in the phase 1 clinical trial of the novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004[12] Financial Strategy - Focus on evorpacept in ASPEN-Breast and ALX2004, while pausing ASPEN-CRC, results in cash runway extended into Q1 2027[12] - The company had cash, cash equivalents, and investments of $84 million as of June 30, 2025[100] Upcoming Milestones - ASPEN-06 CD47 expression data update is expected in Q4 2025[12] - Initial safety data for ALX2004 is anticipated in 1H 2026[12] - ASPEN-breast interim data readout is expected in Q3 2026[12] ASPEN-06 Trial Results - In the ITT population, Evorpacept + TRP showed a 41% ORR compared to 27% in the TRP control arm[42] - In patients with HER2-positivity confirmed by fresh biopsy or ctDNA, evorpacept demonstrated a 49% ORR compared to 245% in control[45] - In patients with HER2+ and CD47-high gastric cancer (n=43), evorpacept + TRP had a 65% ORR versus 26% ORR for TRP[53] ASPEN-Breast Trial - In breast cancer patients with confirmed HER2-positivity, evorpacept + zanidatamab had a 56% confirmed ORR[63]

NASDAQ: SCWO Investor Presentation August 12, 2025 ©2025 374Water Inc. All Rights Reserved. This document and the information set forth herein are the property of 374Water. Clean & Sustainable Destruction of Organic Waste Second Quarter 2025 Strategic and Commercial Update and Financial Results Conference Call Cautionary Statement Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain "forward-looking statements" of 374Water Inc. ("374Water," "the ...

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is developing zorevunersen as a potential disease-modifying medicine for Dravet syndrome [16] - Initial 70mg doses of zorevunersen demonstrated substantial and sustained reductions in convulsive seizure frequency [18] - Ongoing zorevunersen treatment showed substantial and durable reductions in major motor seizure frequency in OLE studies [21] - 36-month OLE data shows continuing improvements in cognition and behavior with zorevunersen treatment [56] - The EMPEROR Phase 3 study is designed to assess disease modification in Dravet syndrome with a dosing regimen of 2x70mg followed by 2x45mg over a 52-week treatment period [31, 32] - The EMPEROR Phase 3 study has dosed its first patient in August 2025 and anticipates data in 2H 2027, randomizing approximately 170 patients across ~70 global sites [35] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - Approximately 65-90% of ADOA cases are caused by mutations in one allele of the OPA1 gene, leading to haploinsufficiency [64] - Up to 46% of ADOA patients are registered as legally blind [65] - Preclinical findings support further development of STK-002, showing increased OPA1 protein and ATP-linked respiration [70] - A Phase 1 study of STK-002 in ADOA patients is underway in the UK, involving 21 patients aged ≥18 to <55 years receiving single ascending doses (0.1, 0.3, 0.5, & 0.7 mg/eye) [76]

Company Overview and Strategy - Mobile Infrastructure owns a diversified portfolio of parking assets primarily in the Midwest and Southwest and aims to improve revenue consistency and NOI margin through conversion from leased to managed contracts[6] - The company's strategic plan focuses on driving NOI growth through asset profile optimization, pivoting to management contracts, implementing an asset management approach, and exploring ancillary revenue opportunities like EV charging[14] - As of June 30, 2025, 29 out of 40 assets have been converted to management contracts, with plans to convert the remaining assets in 2026-2027, which is expected to accelerate revenue growth and cost savings[25] Financial Performance and Valuation - The company's Net Asset Value (NAV) is $7.25 per share, indicating a potentially attractive valuation compared to the higher replacement cost of its assets[6] - For the quarter ended June 30, 2025, managed property revenue was $7441 thousand, while base rental income was $1447 thousand, and percentage rental income was $104 thousand[49] - Net Operating Income (NOI) for the quarter ended June 30, 2025, was $5435 thousand, a decrease of 35% compared to $5633 thousand for the same period in 2024[49] - Adjusted EBITDA for the quarter ended June 30, 2025, was $3846 thousand, compared to $4074 thousand for the same period in 2024[50] Market and Acquisition Strategy - The U S parking industry generates approximately $131 billion in annual revenue, representing about 1% of the U S GDP[28] - The company has a $300 million pipeline of potential acquisitions and intends to become the acquirer of choice in the parking industry through its unique, tax-efficient acquisition program[6, 45]

Financial Performance - H&R Block's FY25 total revenue grew by 42% to $37610 million[12,40] - The company's FY25 EBITDA reached $976 million[13] a 14% increase compared to the previous year's $9632 million[40] - Adjusted earnings per share increased by 57% to $466[40] - H&R Block forecasts FY26 revenue between $3875 billion and $3895 billion and EBITDA between $1015 billion and $1035 billion[48] Capital Allocation - The company increased its quarterly dividend by 12%[14] - H&R Block has repurchased over 43% of its shares outstanding since 2016[16] - The company plans approximately $400 million in share repurchases[49] Business Segments - Small business revenue experienced double-digit growth[27] with overall revenue increasing 13% year-over-year[27] - Newly created Spruce accounts increased by approximately 40% in FY25[29] - Approximately 50% of FY25 deposit transactions originated from non-tax sources[30,32]

Company Highlights - Smart Sand has a total plant annual capacity of approximately 10 million tons [23, 50] - The CEO owns approximately 18% of the company, and insiders own approximately 36% [19, 105] - The company has repurchased approximately 62 million shares since January 2023 [19, 105] - Dividends of $010 per common share were paid in October 2024 and August 2025 [19, 105] Financial Performance - Q2 2025 sales volume was 1424 thousand tons [26] - Q2 2025 revenue was $858 million [28] - Q2 2025 contribution margin per ton was $1108 [29] - Q2 2025 adjusted EBITDA was $7751 thousand [29, 119] Logistics and Operations - The Oakdale facility has 243 million tons of reserves and a 40+ year reserve life [19] - The Ottawa facility has 127 million tons of reserves and a 75+ year reserve life [19] - The Blair facility has 114 million tons of reserves and a 35+ year reserve life [19]

Company Overview - ClearPoint Neuro enables cell, gene, and device therapies by offering precise navigation to the brain and spine[6] - The company's platform includes clinical products for neurosurgeons and drug development services for BioPharma partners[6] - ClearPoint Neuro has built a complete drug delivery ecosystem over 15+ years[8] - The company has 100+ active global centers and 60+ partners across 20+ indications[8] Market Opportunity - The company estimates its current portfolio provides access to a ≈$500 million market opportunity[8] - ClearPoint Neuro sees a $10 billion potential diversified market[9] - Over 30 million people in the U S are estimated to suffer from severe and debilitating neurological disorders[10] - Neurological diseases cost Americans nearly $800 billion annually[10] Financial Performance - The company's 2024 revenue was $31.4 million[52] - As of June 30, 2025, the company had $41.5 million in cash and cash equivalents[52] - The company's gross margin is 60%[52] - The company's 2024 operational cash burn was ($9.0 million)[52]